Integra LifeSciences Holdings Corporation

Good day and welcome to Integra Life Sciences first quarter 2026 financial results. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question, please press star 11 on your touchstone telephone. Also note this call is being recorded. I would like to turn the call over to Chris Ward, Senior Director of Investor Relations. Please go ahead.

Good morning, and thank you for joining the Integral Life Sciences first quarter 2026 earnings conference call. Joining me on the call are Stuart Essig, Chairman, President, and Chief Executive Officer, and Leah Knight, Chief Financial Officer. This morning, we issued two press releases, the first announcing the CEO transition and other organizational changes, and the second announcing our first quarter 2026 financial results. The releases and earnings presentation that we will reference during the call available at integralife.com under investors events and presentations and a file name first quarter 2026 earnings call presentation before we begin I want to remind you that many statements made during this call may be considered forward-looking factors that could cause actual results to differ materially are discussed in the company's exchange act reports filed with the SEC also in our prepared remarks we will reference reported and organic revenue growth Organic revenue growth excludes the effects of foreign currency, acquisitions, and investitures. Unless otherwise stated, all disaggregated and franchise-level revenue growth rates are based on organic performance. Lastly, our comments today will include certain non-GAAP financial measures. Reconciliations of non-GAAP financial measures are included in today's press release, which is an exhibit to Integra's current report on Form 8K, filed today with the SEC. And with that, I will now turn the call over to Stuart.

Thank you, Chris. Before we turn to the quarter, I want to address the leadership change that we announced this morning. As you have seen from our announcement, I have stepped back into the role as president and CEO and will retain my current role as chairman. I want to thank Mojdeh Pol for her leadership and for the meaningful progress made during her tenure. Under her leadership, the company advanced a number of important initiatives, including enterprise-wide portfolio and program prioritization, risk-based approach to quality remediation work, operations resiliency improvements, and the more recent transformation and business process optimization efforts. Those efforts matter, and they are progressing well, and we remain fully committed to them. As I step back into the CEO role, my focus will be on strengthening the culture of the organization while increasing our customer and commercial focus. We want to be more connected to our customers, more aligned with the field, more collaborative across functions, and clearer and faster in our execution. We're building on the important work already underway while improving how we work together and how quickly we make things happen. We remain committed to the quality, compliance, capacity, and transformation work underway across the company. That work is progressing well and remains central to how we improve performance and build a stronger integra. As we also announced this morning, Mike McBreen has been appointed Chief Commercial Officer. Some of you already know Mike well. He is exceptionally well suited for this role with more than 30 years of commercial experience in the medical technology industry. This newly created role is an important part of how we move forward. and Mike will help drive the next phase of our commercial organization. This move reflects the importance we place on making sure the commercial organization has a strong voice at the leadership table and that customer and market-facing priorities are fully represented in how we operate and make decisions. This is not about changing direction in the commercial organization. It is about raising its profile, strengthening leadership support around it, and better positioning us to succeed. Our commercial teams have many strengths, and Mike's expanded role is intended to help us build on that momentum, sharpen execution, and support stronger coordination across the market facing parts of the business. This appointment also reflects something broader that matters deeply to me as I return to the CEO role. I want to make sure we are developing the next layer of leadership across the company. and giving strong leaders the opportunity to take on larger responsibilities. Mike's new role as CCO supports that objective and will allow me to devote more direct time and attention to the areas that still require the greatest focus. This is the kind of leadership model that I want to reinforce across Integra, one that is customer-centered, commercially aware, collaborative, accountable, and focused on helping the organization succeed. We want our support functions and leadership teams working the way that enables the business, supports the field, and drives results. That is the cultural tone we intend to reinforce. I also want to be clear that I'm not stepping in as a transitional CEO. I am assuming this role with a long-term commitment and deep familiarity with the company and its operations. I have served Integra in various capacities as CEO, executive chairman, and chairman for almost 30 years. Over the past two years, I have been actively involved in key initiatives as executive chairman, including active oversight of key operational and quality matters. These included the implementation of the compliance master plan, the Integra skin capacity expansion, the initiation of the Braintree facility program, and direct communication with investors about the company's progress and path forward. I know this company deeply, I understand what it takes to run it, and I have a clear view of what I believe it will take to move Integra forward from here. So the message today is straightforward. The important work already underway is continuing. It's going well, and it remains central to building a stronger Integra. At the same time, we are sharpening our focus on culture, customers, and commercial execution at the top of the organization. I remain confident both the progress we've made and the opportunity ahead. It is an honor and a privilege to lead this fine organization once again. With those important announcements in mind, I'd like to now turn to our results on slide four. We had a very strong first quarter, and the team demonstrated what it can achieve as we continue to improve product availability. For the first quarter, we delivered total revenue of $392 million, and adjusted earnings per share of 54 cents, both above the high end of our guidance ranges. Based on our first quarter performance and the strengthening of our foundation, we are maintaining our 2026 revenue guidance of $1.66 billion to $1.7 billion and updating our adjusted earnings per share guidance to a range of $2.40 to $2.50. Leah will now walk through our first quarter results and guidance in more detail.